Skip to main content

Year: 2021

Regarding the AB “Ignitis grupė” intention to loan up to EUR 300m

Regarding the AB “Ignitis grupė” intention to loan up to EUR 300m to UAB “Ignitis” AB “Ignitis grupė” (hereinafter – the Group) informs that on 22 November 2021 the Group Supervisory Board approved the conclusion of the loan agreement, which would not exceed EUR 300m, (hereinafter – the Loan) with UAB “Ignitis” (hereinafter – Ignitis). The approval of the Loan was also submitted by the Group Audit Committee. The funds from the Loan will be allocated, as necessary, to finance differences between actual electricity/natural gas purchase prices and the approved tariffs for household consumers throughout 2021–2022. The amortisation of increased prices for more gradual changes for household consumers in electricity tariff is possible for a period shorter than until 31 December 2027, and in the natural gas tariff – shorter than 5 years from the...

Continue reading

Regarding the AB “Ignitis grupė” intention to loan up to EUR 300m to UAB “Ignitis”

AB “Ignitis grupė” (hereinafter – the Group) informs that on 22 November 2021 the Group Supervisory Board approved the conclusion of the loan agreement, which would not exceed EUR 300m, (hereinafter – the Loan) with UAB “Ignitis” (hereinafter – Ignitis). The approval of the Loan was also submitted by the Group Audit Committee. The funds from the Loan will be allocated, as necessary, to finance differences between actual electricity/natural gas purchase prices and the approved tariffs for household consumers throughout 2021–2022. The amortisation of increased prices for more gradual changes for household consumers in electricity tariff is possible for a period shorter than until 31 December 2027, and in the natural gas tariff – shorter than 5 years from the regulatory period for which the estimated natural gas (product) price reduction...

Continue reading

AUGA group, AB will organise an Investor Conference Webinar to introduce unaudited financial results for the 9 months of 2021

AUGA group, AB invites shareholders, investors, analysts, and other stakeholders to join the webinar scheduled on December 1 of 2021 at 4.00 PM (EET). The presentation will be held in English.  During the webinar, Kęstutis Juščius, CEO of AUGA group and Mindaugas Ambrasas, CFO of AUGA group will introduce the performance and unaudited financial results of the company for the 9 months of 2021.  After the presentation participants of the webinar will have an opportunity to ask relevant questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until November 30 to  emilija.ivanauskaite@nasdaq.com . To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/8367447733736146447 You will be provided with the webinar link and instructions how to join successfully....

Continue reading

Critical Solutions, Inc. (CSLI) 3Q Reporting of 127% YTD Gains of Total Assets

From Dormant Caveat Emptor Shell to a Thriving Multi-Industry Holding Company SHERIDAN, WY, Nov. 22, 2021 (GLOBE NEWSWIRE) — ‌Critical‌ ‌Solutions,‌ ‌Inc.‌ ‌ (OTC‌ ‌Pink:‌ ‌CSLI)‌ proudly announces the completion of 3rd Quarter 2021 consolidated statement of earnings and liabilities. Sam Barraza, President,‌ ‌states,‌ “This time last year the company made the announcement it had become Pink Current with OTC markets and would enter into the cannabis, real estate, and crypto markets. We are proud to say that in one-year Critical Solutions has completed these goals and is entering a phase where all the investments of time, energy, and money are paying dividends to the company and will further drive shareholder value. It is Important to note the company has officially completed the Share Exchange and consolidation of all assets from...

Continue reading

Legato Merger Corp. II Announces Pricing of Upsized $240,000,000 Initial Public Offering

NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) — Legato Merger Corp. II (the “Company”) announced today that it priced its upsized initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading later today under the ticker symbol “LGTOU”. Each unit consists of one share of common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the common stock and redeemable warrants are expected to be listed on Nasdaq under the symbols “LGTO” and “LGTOW,” respectively.  Legato Merger Corp. II is a Delaware corporation...

Continue reading

SFIO Acquires PH-based Tech and Software Development Hub LNS+ to Establish Global, Cross-Industry Innovation Ecosystem

The acquisition brings a full suite of tech platform development and maintenance capacities to the asset management companies; As part of SFIO’s investment roadmap into future-oriented industries, establishing LEENTech Network Systems as the group’s new Technology and Software Development division creates new avenues for collaborative innovation across SFIO’s diverse portfolio of companies NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) — Earlier this week, OTC:SFIO Starfleet Innotech, Inc. (Smokefree Innotec, Inc.) announced its acquisition of Philippine-based software development company LEENTech Network Solutions (LNS+), marking the asset management company’s new direction towards technology development. With LNS+ and its subsidiaries now onboard, SFIO is formalizing the team into their new Technology and Software Development Division. According...

Continue reading

Vivos Inc Announces John Hopkins University as a New Regional Clinic for Isopet®

Richland WA, Nov. 22, 2021 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various specific cancers. They have the required radioactive material license and have completed their training certification for Isopet®. Dr. Mike Korenko stated, “Our business plan is to establish new IsoPet® regional centers across the United States and then internationally. John Hopkins University has an excellent reputation and we are excited to add Johns Hopkins as an Isopet® regional clinic. This important relationship will also help meet our objective of obtaining high quality data on a range of cancers that can be published in leading journals....

Continue reading

8i Acquisition 2 Corp. Announces Pricing of $75 Million Initial Public Offering

Singapore, Nov. 22, 2021 (GLOBE NEWSWIRE) — 8i Acquisition 2 Corp. (the “Company”), a newly organized blank check company incorporated as a British Virgin Islands business company and led by Chief Executive Officer, Meng Dong (James) Tan, today announced the pricing of its initial public offering of 7,500,000 units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share, one redeemable warrant, and one right to receive one-tenth (1/10) of an ordinary share. Each whole warrant will entitle the holder thereof to purchase purchase one-half (1/2) of one ordinary share, and each ten rights entitle the holder thereof to receive one ordinary share. The exercise price of the warrants is $11.50 per full share. The units are expected to trade on the Nasdaq Global Market, (“Nasdaq”) under the ticker symbol...

Continue reading

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, enrollment was suspended in 2020 due to COVID-19 restrictions. Those restrictions have now been lifted and patient recruitment has resumed (Clinical trials registry NCT03027388). Up to 20 patients may be enrolled to obtain 8 evaluable subjects. A two-stage design will be used. Five patients will be initially treated. If at least 1 of 5 demonstrates the presence of LB-100 in tumor tissue, 3 additional...

Continue reading

NSAV ANNOUNCES DECEMBER 6, 2021 LAUNCH DATE FOR PRIVATE SALE OF ITS NSAVDEX NATIVE TOKEN, THE NSBC, AND ENTRY INTO MULTI-BILLION DOLLAR MARKET

London, England, Nov. 22, 2021 (GLOBE NEWSWIRE) — Net Savings Link, Inc. (OTC Pink: NSAV), a cryptocurrency, blockchain and digital asset technology company, today announced that the Private Sale of its NSAVDEX Native Token (NSBC) will commence on December 6, 2021 at 11:00 AM EST. The Company has set aside 10 million NSBC tokens for the private sale at 0.10 USDT per token. The NSBC (NSAV Blockchain) is the native token for the recently launched NSAVDEX Decentralized Cryptocurrency Exchange https://nsavdex.org/#/home . An NSAV shareholder conference call will be announced in the coming days to inform shareholders of the financial and technical aspects of the NSBC token and private sale. For further information, please contact the Company on our official DEX Telegram at https://t.me/NSAVDEXorg . The NSAVDEX native token will be using...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.